Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
University of Chicago
Summary
(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.
Description
This study aims to determine whether preemptively obtained pharmacogenomic information can be delivered and utilized at the point-of-care across multiple institutions specifically in African American patients at risk for minority health disparities. The investigators have chosen the high-stakes, rapid-paced setting of inpatient medicine for this implementation study. The investigators seek to examine whether the availability of pharmacogenomic information improves prescribing. The investigators will enroll adults at one of three institutions, The University of Chicago, University of Illinois…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must be at least 18 years of age. * Patients must self-identify as African American Exclusion Criteria: * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Patients with known active or prior leukemia. * Inability to understand and give informed consent to participate. * For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance \<30 mL/min34.
Locations (2)
- The University of Illinois at ChicagoChicago, Illinois
- Northwestern UniversityChicago, Illinois